SCHEMBL607698

SCHEMBL607698

OCCOCCOCCOCCOCCOCCOCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.58
NAAA Q02083 1/20 0.53
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.45
RECQL P46063 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 1/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
HTT P42858 1/20 0.44
MAPK1 P28482 1/20 0.43
IDO1 P14902 1/20 0.43
LTA4H P09960 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triethylene Glycol SCHEMBL29103842 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL24748 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL607716 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL16437096 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL599527 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL12865302 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL3552086 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL16437099 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL606328 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL851320 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
US-20250161459-A1 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2025-05-22 US disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
EP-4475837-A2 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF Adarx Pharmaceuticals, Inc. (US) 2024-12-18 EP disclosed
WO-2024220930-A2 MAPT-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF ADARX PHARMACEUTICALS, INC. (US) 2024-10-24 WO disclosed
CN-118373729-A Synthesis method of small molecule monodisperse polyethylene glycol 扬州市普林斯医药科技有限公司 2024-07-23 CN disclosed
US-20240238424-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2024-07-18 US disclosed
EP-3702434-B1 LUBRICANT COMPOSITION MITSUBISHI CORP (JP) 2024-07-03 EP disclosed
CN-115058280-B Lubricating oil composition and method for producing same 株式会社力森诺科 2024-02-13 CN disclosed
WO-2023154896-A2 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2023-08-17 WO disclosed
WO-2002024623-A2 NOVEL ALKANOIC ACID DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-03-28 WO disclosed
US-6355646-B1 IMMUNOLOGY TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS SEPTIC SHOCK GLAXO WELLCOME INC. 2002-03-12 US disclosed
EP-1104422-A1 PHENYL XANTHINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-06-06 EP disclosed
WO-2000009507-A1 PHENYL YANTHINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2000-02-24 WO disclosed
EP-0970081-A1 SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS GLAXO GROUP LIMITED (GB) 2000-01-12 EP disclosed
WO-1998035966-A1 SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS GLAXO GROUP LIMITED (GB) 1998-08-20 WO disclosed
EP-0341409-B1 Platinum (II) complexes, their preparation and use as antitumour agents BOEHRINGER MANNHEIM ITALIA (IT) 1993-12-29 EP disclosed
EP-0415939-A1 PLATINUM(II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-TUMOUR AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1991-03-13 EP disclosed
EP-0341409-A1 Platinum (II) complexes, their preparation and use as antitumour agents BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1989-11-15 EP disclosed
WO-1989009218-A1 PLATINUM(II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-TUMOUR AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1989-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238424-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE MDM2, VHL, TP53 TSHR 4338/4885NAAA 3269/4885KDM4E 1960/4885
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 TSHR 70/4885NAAA 3147/4885KDM4E 1888/4885
US-20250161459-A1 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF NTRK2, NTRK1, BDNF TSHR 208/4885NAAA 2617/4885KDM4E 3416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.